NovaBay Pharmaceuticals to Hold 2015 Fourth Quarter and Full Year Conference Call on March 3

EMERYVILLE, Calif.--()--NovaBay® Pharmaceuticals, Inc. (NYSE MKT: NBY), a biopharmaceutical company focusing on commercializing its Avenova® Lid and Lash Cleanser for the domestic eye care market, announces that it will report 2015 fourth quarter and full year financial results after market close on Thursday, March 3. Management will hold an investment community conference call to discuss financial results and provide a company update.

     
DATE: Thursday, March 3, 2016
 
TIME: 4:30 p.m. Eastern time / 1:30 p.m. Pacific time
 
DIAL IN: 866-239-5859 from within the U.S.

702-495-1913 from outside the U.S.

Enter conference identification number 59218506
 

The live call also will be available at http://novabay.com/investors/events. A replay of the call will be available beginning two hours after its completion through 11:59 p.m. Eastern time March 9, 2016, by dialing 855-859-2056 from within the U.S. or 404-537-3406 from outside the U.S. and entering the conference identification number 59218506. The call will also be archived at http://novabay.com/investors/events.

About NovaBay Pharmaceuticals, Inc.: Going Beyond Antibiotics
NovaBay Pharmaceuticals is a biopharmaceutical company focusing on the commercialization of prescription Avenova® Lid and Lash Cleanser for the eye care market. Avenova is formulated with Neutrox™, which is cleared by the U.S. Food and Drug Administration (FDA) as a 510(k) medical device. Neutrox is NovaBay’s pure hypochlorous acid. Laboratory tests show that hypochlorous acid has potent antimicrobial activity in solution yet is non-toxic to mammalian cells and it also neutralizes bacterial toxins. Avenova is marketed to optometrists and ophthalmologists throughout the U.S. by NovaBay’s direct medical salesforce. It is accessible from more than 90% of retail pharmacies in the U.S. through agreements with McKesson Corporation, Cardinal Health and AmeriSource Bergen.

Stay informed on NovaBay's progress:
Download our Mobile InvestorApp from the Apple Store or Google Play
Like us on Facebook
Follow us on Twitter
Connect with NovaBay on LinkedIn
Join us on Google+
Visit NovaBay's Website

Contacts

NovaBay Contacts
For NovaBay Avenova purchasing information, please contact:
Email us
Call us: 1-800-890-0329
www.Avenova.com
or
From the Company
Thomas J. Paulson
Chief Financial Officer
510-899-8809
Contact Tom
or
Investor Contact
LHA
Jody Cain, 310-691-7100
jcain@lhai.com

Release Summary

NovaBay Pharmaceuticals to report 2015 fourth quarter and full year financial results on March 3

$Cashtags

Contacts

NovaBay Contacts
For NovaBay Avenova purchasing information, please contact:
Email us
Call us: 1-800-890-0329
www.Avenova.com
or
From the Company
Thomas J. Paulson
Chief Financial Officer
510-899-8809
Contact Tom
or
Investor Contact
LHA
Jody Cain, 310-691-7100
jcain@lhai.com